Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients. - Wikidata - wikimedia - TriplyDB

Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.

Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.

http://www.wikidata.org/entity/Q38052616

about

Duration of trastuzumab in patients with HER2-positive metastatic breast cancer in prolonged remission Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.Autophagy proteins regulate cell engulfment mechanisms that participate in cancer.Mass spectrometric protein maps for biomarker discovery and clinical research.Hepatitis B virus X upregulates HuR protein level to stabilize HER2 expression in hepatocellular carcinoma cells.Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.Qualification and Verification of Protein Biomarker Candidates.Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.Long-responders to anti-HER2 therapies: A case report and review of the literature.A correlation study of the expression of HA-CD44st and HER-2 in breast cancer

P2860

Q26749255-CE51517A-81BF-4374-ABEC-1B70FAF31FC6 Q35915735-DC051B3B-8870-41CF-971B-9AA10801910E Q37216731-D707CCBC-C7EE-4010-BCA0-24F2E1CB6A91 Q37324690-42C201EC-0380-4212-9CB6-BAB284313A3D Q37639917-E168B69F-B9AA-4837-9A5B-131B5BB3C25D Q38661390-197FB0F7-6AA1-426E-9E75-66EA8DACAAFE Q39099858-CF7F054A-E12B-477D-BD72-01ACD3C61707 Q41037554-9A988AD2-6F21-45C3-B9B6-7BA21A4F098A Q49311135-EF214726-D55D-4A4A-9F51-5AF64F93DAF4 Q58754066-D9CCBB9F-3A8B-4034-8B61-54D1E8CC3603

P2860

Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.

http://www.wikidata.org/entity/Q38052616

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.

@en

type

label

Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.

@en

prefLabel

Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.

@en

P1433

Q38052616-BC787B5F-5075-474E-86D6-44788BFE981A

P1476

Q38052616-16937F33-C1F5-47EB-A740-EB0C24639B6F

P2093

Q38052616-258919BA-4956-4663-8AFE-B261F81AA767

Q38052616-3FA2E50F-99DE-46DA-AD78-2DF7EACABCC4

Q38052616-D3FA33F0-1182-4174-BED1-34B7775DB24D

P2860

Q38052616-02FE6D1C-BE2C-4FD9-BE41-C1312158A4A0

Q38052616-04DDDB75-A0C9-4F56-9083-6865D0C688AB

Q38052616-08D23606-9F97-46BB-B91D-10CCBD20ACDA

Q38052616-105E91D1-936C-4E55-AD89-44A2876F7846

Q38052616-13C980E6-955B-4BDE-A715-CF641D1145A5

Q38052616-15D006A0-224C-4751-9912-702D4D89E93E

Q38052616-1739DF62-6461-40DB-85B8-325A5E96512F

Q38052616-226C69E9-B4BA-41AF-92FE-DD7D05584A3E

Q38052616-24A6C6E5-2F2F-4EDD-9EB5-6C3D664CE4A0

Q38052616-289DF14A-A251-48DF-8A42-9A03FB289040

P304

Q38052616-99E673A0-6C24-4C01-9684-FEC47FEA66B7

P31

Q38052616-9D584923-349C-4678-8ED4-9E3BE6DFB751

P356

Q38052616-51327668-CFB3-40EE-B78A-1024D10419EB

P433

Q38052616-9495C22D-9CB1-43B1-BB84-F34BD86A1D85

P478

Q38052616-A4F7B556-9C23-4BFB-B9BE-A07DEAECE9D6

P50

Q38052616-39D0C6C8-6403-4D0C-8860-6FEC49A151BE

Q38052616-73EF356B-15EA-4308-BB0D-A9E4C4C774FD

Q38052616-78D9811B-A4A6-479D-B531-50807A2498F0

Q38052616-F3D151F8-8E16-406E-8A5F-19A2E9387071

P577

Q38052616-706B2194-3910-45FB-B7AC-C3C55128398D

P698

Q38052616-8EF50499-10FB-4D02-9C69-768EE11DCCD4

P356

P1433

Expert Review of Anticancer Therapy

P1476

Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients.

@en

P2093

Alessia D'Alonzo

http://www.w3.org/2001/XMLSchema#string

Alessia Levaggi

http://www.w3.org/2001/XMLSchema#string

Sara Giraudi

http://www.w3.org/2001/XMLSchema#string

P2860

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Untangling the ErbB signalling network

P304

1391-1405

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERA.12.107

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Matteo Lambertini

Lucia Del Mastro

P577

2012-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23072512

http://www.w3.org/2001/XMLSchema#string